Definitions

from Wiktionary, Creative Commons Attribution/Share-Alike License

  • n. A humanized monoclonal antibody used to treat cancer.

Etymologies

-tu- +‎ -zu- +‎ -mab (Wiktionary)

Examples

  • The company said in a press release Monday morning that it would discontinue development of the drug, called lintuzumab, which might have been its first product to reach the market.

    NYT > Home Page

  • The company said in a news release Monday morning that it would discontinue development of the drug, called lintuzumab, which could have been its first product to reach the market.

    NYT > Business Day

  • Unlike lintuzumab, which is an older "naked" antibody, SGN35 is a conjugate made up of a tumor-targeting antibody linked to a chemotherapy drug called monomethyl auristatin E.

    Latest financial, market & economic news and analysis | guardian.co.uk

  • The Bothell, Wash., biotechnology company said it will end development of its experimental leukemia drug lintuzumab after a mid-stage trial of the treatment on older patients didn't meet its primary endpoint of extending overall survival.

    ArcSight Bid Drives Up Tech Sector

  • While the focus may be on SGN-35, a surprise may lie in store with its other advanced candidate, the naked antibody SGN-33 (lintuzumab).

    SeekingAlpha.com: Home Page

  • In addition, Seattle Genetics has four other product candidates in ongoing clinical trials: lintuzumab (SGN-33), dacetuzumab (SGN-40), SGN-70 and SGN-75.

    The Earth Times Online Newspaper

  • Fourth quarter 2009 expenses decreased compared to the fourth quarter of 2008 as a result of lower manufacturing costs for dacetuzumab and brentuximab vedotin, and decreased lintuzumab clinical trial costs.

    The Earth Times Online Newspaper

  • Operating expenses will be primarily directed towards brentuximab vedotin pivotal development and pre-commercialization activities, as well as development and clinical activities for lintuzumab, SGN-75 and ASG-5ME.

    The Earth Times Online Newspaper

  • Seattle Genetics has four other product candidates in ongoing clinical trials: lintuzumab

    The Earth Times Online Newspaper

  • Continued patient treatment and follow-up in a randomized phase IIb trial of lintuzumab plus low-dose chemotherapy for patients 60 years and older with acute myeloid leukemia to determine if the combination extends overall survival; data from this trial are expected in the second quarter of

    The Earth Times Online Newspaper

Comments

Log in or sign up to get involved in the conversation. It's quick and easy.